Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Brainstorm Cell Therapeutics reports financials, faces credibility challenges on unblinding

Brainstorm Cell Therapeutics showcased financial investment in R&D and highlighted positive testimonials for NurOwn's ALS treatment.
Maintaining blinding for trial integrity and emphasizing industry best practices demonstrate commitment to ethical standards.
Challenges include balancing individual requests for unblinding with overall trial integrity and addressing concerns around credibility.
Opportunities lie in enhancing communication, addressing unblinding concerns, and leveraging community support for market access.

Brainstorm Cell Therapeutics advances NurOwn towards regulatory approval amidst financial constraints

Brainstorm Cell Therapeutics showcased progress in regulatory milestones, clinical data analysis, and organizational enhancements during the Q1 2023 Earnings Call
While demonstrating strengths in clinical efficacy and strategic leadership appointments, the company faces challenges in financial constraints and the need for further clarity in certain areas
Opportunities lie in advancing towards regulatory approval, leveraging strategic hires for growth, and exploring diversification through international expansion and innovation

BrainStorm Cell Therapeutics readies for FDA review of NurOwn

BrainStorm Cell Therapeutics is actively preparing for the FDA review of NurOwn, with a focus on commercial readiness and engaging with physicians. Despite financial challenges, the company raised funds and is optimistic about future growth. BrainStorm's expansion into new indications and potential collaborations highlight strategic opportunities for the company.

Brainstorm Cell Therapeutics adjusts strategy post BLA withdrawal

Brainstorm Cell Therapeutics navigated challenges with a strategic realignment and capital constraints.
The company is focusing on partnerships, exosome technology, and advancing their ALS program.
Opportunities lie in raising capital, exploring collaborations, and leveraging exosome technology.
Seeking regulatory de-risking and diversification through exosome tech are key strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.

BrainStorm Cell Therapeutics' (BCLI) CEO Chaim Lebovits on Q3 2019 Results - Earnings Call Transcript

NEW YORK, Nov.  14, 2019  (GLOBE NEWSWIRE) --  BrainStorm Cell Therapeutics, Inc . ( NASDAQ:BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that the Company has received a $495,330 grant from the National Multiple Sclerosis Society, through its Fast Forward program, to advance BrainStorm’s Phase 2 open-label, multicenter clinical trial of repeated intrathecal administration of NurOwn® (autologous MSC-NTF cells) in participants with progressive Multiple Sclerosis ( NCT03799718 ).

BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society

NEW YORK, Nov.  12, 2019  (GLOBE NEWSWIRE) --  BrainStorm Cell Therapeutics, Inc . ( NASDAQ:BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company’s Chief Operating and Chief Medical Officer Ralph Kern MD MHSc will present at the  7  th   International Stem Cell Meeting , which is hosted by the  Israel Stem Cell Society . The Conference will be held November 12-13, in Tel Aviv, Israel. 

BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting

Interview With Chaim Lebovits, CEO Of Brainstorm Cell Therapeutics

NEW YORK, Oct.  28, 2019  (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. ( NASDAQ: BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Phase 3 clinical trial independent Data Safety Monitoring Board (DSMB) has completed the second, pre-specified interim analysis, of safety outcomes for the first 106 patients who received repeat dosing of NurOwn® in the Phase 3 trial for ALS patients ( NCT03280056 ). The DSMB indicated that the Phase 3 clinical trial should continue as planned.

NurOwn® Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue

NEW YORK, Oct.  25, 2019  (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that it will be presenting at the  Dawson James Securities 5th Annual Small Cap Growth Conference , being held on October 28-29, 2019 at the Wyndham Grand Hotel in Jupiter, Florida.

BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

NEW YORK, Oct.  24, 2019  (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced, Chaim Lebovits, President and CEO, will serve as a Keynote Speaker at Cell Series UK. Cell Series UK, will be held October 29-30, 2019, at London Novotel West, London, UK.  The Conference, organized by Oxford Global, is one of the foremost events in Europe focused on  regenerative medicine and cellular innovation.  

BrainStorm Cell Therapeutics’ President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019

NEW YORK, Oct.  23, 2019  (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will be participating and presenting scientific data at the upcoming  Neuromuscular Drug Development Summit , from October 23-25th, in Boston MA.  The Summit is dedicated to solving the challenges in developing second generation neuromuscular therapeutics.

BrainStorm Cell Therapeutics Presentations at Neuromuscular Drug Development Summit

NEW YORK, Oct.  11, 2019  (GLOBE NEWSWIRE) --  BrainStorm Cell Therapeutics, Inc . ( NASDAQ: BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it has fully enrolled the 200-patient Phase 3 clinical trial evaluating repeat intrathecal administration of NurOwn® Cellular Therapeutic (autologous MSC-NTF cells) in ALS (Amyotrophic Lateral Sclerosis). BrainStorm’s Phase 3 clinical trial is being conducted at the  University of California, Irvine ;  Cedars-Sinai Medical Center ;  California Pacific Medical Center ;  Massachusetts General Hospital ;  University of Massachusetts Medical School ; and the  Mayo Clinic .

BrainStorm’s NurOwn® Phase 3 ALS Clinical Trial Now Fully Enrolled

NEW YORK, Oct.  07, 2019  (GLOBE NEWSWIRE) --  BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the United States Patent and Trademark Office ( USPTO ) has issued a Notice of Allowance for BrainStorm's new US Patent Application, number: 15/113,105, titled: ‘Method of Qualifying Cells'.

BrainStorm Announces Notice of US Patent Allowance for NurOwn® Cellular Therapeutic Technology Platform

NEW YORK, Oct.  02, 2019  (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases announced today, Chief Operating Officer and Chief Medical Officer, Ralph Kern, MD, MHSc, will present NurOwn® Phase 2 biomarker data at the 18th Annual  NEALS Meeting  held October 2-4, 2019 in Clearwater, Florida.  In addition, Dr. Kern will represent BrainStorm at the NEALS member/industry partner roundtable that will discuss the evolving landscape of ALS clinical trials and potential surrogate and functional endpoints for regulatory approval.

BrainStorm Cell Therapeutics to Present NurOwn® Phase 2 Biomarker Data at North East Amyotrophic Lateral Sclerosis (NEALS) 18th Annual Meeting

BrainStorm Holds a Roundtable Discussion with ALS Advocacy Group Leaders BrainStorm Holds a Roundtable Discussion with ALS Advocacy Group Leaders

BrainStorm Cell Therapeutics Announces Support for FDA Guidelines on ALS Drug Development

NEW YORK, Sept.  09, 2019  (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that Preetam Shah, Ph.D., M.B.A., has been appointed Chief Financial Officer effective September 6, 2019. 

BrainStorm Strengthens Senior Executive Management Team with the Appointment of Preetam Shah, Ph.D., M.B.A., as Chief Financial Officer

NEW YORK, Sept.  06, 2019  (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will present scientific data at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS, www.ectrims-congress.eu), September 11-13th in Stockholm, Sweden.

BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress

BrainStorm Cell Therapeutics' (BCLI) CEO Chaim Lebovits on Q2 2019 Results - Earnings Call Transcript

News for Brainstorm Cell Therapeutics Stock (BCLI)